Table 1.
Baseline characteristics and outcomes for the cohort (n = 12,936)
| Variable | Death within 14 d (N = 563, 4.35%) | Survival (N = 12,373, 95.65%) | P-value |
|---|---|---|---|
| Male | 549 (97.5%) | 11,619 (93.9%) | .0004 |
| Age | 76.9 ± 10.03 | 68.1 ± 13.8 | <.0001 |
| Age ≥65 | 507 (90.1%) | 8,238 (66.6%) | <.0001 |
| Race | .0530 | ||
| African American | 139 (24.7%) | 3,459 (28.0%) | |
| White | 382 (67.9%) | 7,781 (62.9%) | |
| Other | 42 (7.5%) | 1,133 (9.2%) | |
| Body mass index | 26.8 ± 6.99 | 28.56 ± 7.21 | <.0001 |
| Charlson comorbidity Index | <.0001 | ||
| 0-5 | 357 (63.4%) | 9,676 (78.2%) | |
| 6-20 | 206 (36.6%) | 2,697 (21.8%) | |
| CAHD | 241 (42.8%) | 4,178 (33.8%) | <.0001 |
| Cancer | 193 (34.3%) | 3,544 (28.6%) | .0039 |
| Cardiomyopathy | 69 (12.3%) | 1,115 (9.0%) | .0090 |
| Cerebrovascular | 31 (5.5%) | 661 (5.3%) | .8657 |
| Congestive heart failure | 185 (32.9%) | 2,772 (22.4%) | <.0001 |
| Cirrhosis | 42 (7.5%) | 599 (4.8%) | .0051 |
| Chronic kidney disease | 252 (44.8%) | 3,717 (30.0%) | <.0001 |
| Chronic obstructive pulmonary disease | 202 (35.9%) | 3,609 (29.2%) | .0006 |
| CVD | 379 (67.3%) | 7,103 (57.4%) | <.0001 |
| Diabetes | 291 (51.7%) | 5,590 (45.2%) | .0024 |
| HIV | 4 (0.7%) | 123 (1.0%) | .5044 |
| Hypertension | 475 (84.4%) | 9,524 (77.0%) | <.0001 |
| Dexamethasone | 374 (66.4%) | 5,028 (40.6%) | <.0001 |
| Vaccinated (2 doses) | 258 (45.8%) | 6,726 (54.4%) | <.0001 |
| Vaccinated (3 doses) | 73 (13.0%) | 2,475 (20.0%) | <.0001 |
| Ventilator within 60 d | 192 (34.1%) | 723 (5.8%) | <.0001 |
| Length of stay | 6.12 ± 3.7 | 7.8 ± 7.97 | <.0001 |
| Death within 30 d | 563 (100%) | 437 (3.5%) | <.0001 |
| Readmission within 30 d | 23 (4.1%) | 1,517 (12.3%) | <.0001 |
| ICU within 60 d | 384 (68.2%) | 3,210 (25.9%) | <.0001 |
CAHD, coronary atherosclerotic heart disease; CVD, cardiovascular disease; HIV, human immunodeficiency virus; ICU, intensive care unit.